<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941404</url>
  </required_header>
  <id_info>
    <org_study_id>TQ05105-Ib-01</org_study_id>
    <nct_id>NCT04941404</nct_id>
  </id_info>
  <brief_title>A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)</brief_title>
  <official_title>A Single Arm, Open-label, Multicenter, Phase Ib Study of TQ05105 Tablets in Subjects With aGVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability,&#xD;
      preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with&#xD;
      Glucocorticoid-Refractory aGVHD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug tolerance of the first cycle (Stage 1)</measure>
    <time_frame>Day 28 after initial administration</time_frame>
    <description>Dose-limiting toxicity events related to the investigational drug occured within 28 days after initial administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) at Day 28 (Stage 2)</measure>
    <time_frame>Day 28 after initial administration</time_frame>
    <description>Percentage of subjects with complete response (CR) or very good partial response (VGPR) or partial response (PR) at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR Rate at Day 28</measure>
    <time_frame>Day 28 after initial administration</time_frame>
    <description>Percentage of subjects with CR at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR at Day 28 and Day 56</measure>
    <time_frame>Day 28 and Day 56 after initial administration</time_frame>
    <description>Percentage of subjects with CR or VGPR or PR at Day 28 and Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From initial administration to day 30 after the last administration</time_frame>
    <description>From date of first recorded remission to date of first recorded disease progression or date of starting any new systemic therapy for aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of glucocorticoid at Day 56</measure>
    <time_frame>Day 56 after initial administration</time_frame>
    <description>Totally and weekly cumulative dose of glucocorticoid of each subject,from initial administration to Day 56 or the day end of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS）</measure>
    <time_frame>From initial administration to Day 30 day after the last administration</time_frame>
    <description>From the date of initial administration to the date of recurrence/progression of hematological diseases or transplant failure or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From initial administration to day 30 days after the last administration</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malignancy Relapse/Progression(MR),Non-Relapse Mortality(NRM)</measure>
    <time_frame>From initial administration to 30 days after the last administration</time_frame>
    <description>From the date of first administration to the date of death due to recurrence/progression of non hematological diseases; the date of recurrence or progression of hematological diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From initial administration to day 30 after the last administration</time_frame>
    <description>Incidence of AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>7 days after initial administration</time_frame>
    <description>The pharmacokinetic parameters were measured after single and multiple administration: peak time(Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>7 days after initial administration</time_frame>
    <description>The pharmacokinetic parameters were measured after single and multiple administration: peak concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>7 days after initial administration</time_frame>
    <description>The pharmacokinetic parameters were measured after single and multiple administration: area under the blood concentration-time curve (AUC0-t)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Glucocorticoid-Refractory aGVHD</condition>
  <arm_group>
    <arm_group_label>TQ05105 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ05105 tablets</intervention_name>
    <description>Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.</description>
    <arm_group_label>TQ05105 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects voluntarily participated in the study and signed an informed consent, with&#xD;
             good compliance.&#xD;
&#xD;
          2. Aged 12-75, gender is not limited.&#xD;
&#xD;
          3. Subjects who has received allogeneic hematopoietic stem cell transplantation&#xD;
             (allo-HSCT) previously.&#xD;
&#xD;
          4. Clinically suspected grades II to IV acute GVHD as per MAGIC guidelines.&#xD;
&#xD;
          5. Drug resistance after glucocorticoid treatment.&#xD;
&#xD;
          6. Absolute neutrophils count (ANC) &gt;1×109/L,Platelet(PLT)≥20×109/L within 48 hours&#xD;
             before initial treatment.&#xD;
&#xD;
          7. Male or female subjects should agree use an adequate method of contraception during&#xD;
             the study and within 6 months after the end of the study (such as intrauterine devices&#xD;
             , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative&#xD;
             pregnancy test are received within 7 days before the first administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of progressive multifocal leukoencephalopathy.&#xD;
&#xD;
          2. Subjects with many factors influencing oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction, etc.).&#xD;
&#xD;
          3. Arteriovenous thrombotic events occurred within 6 months, such as cerebrovascular&#xD;
             accident (including transient ischemic attack, cerebral hemorrhage, cerebral&#xD;
             infarction), deep vein thrombosis, etc..&#xD;
&#xD;
          4. Severe respiratory diseases (requiring mechanical ventilation or O2 saturation &lt; 90%),&#xD;
             active tuberculosis, pulmonary hypertension and pulmonary embolism, etc..&#xD;
&#xD;
          5. Subjects with a history of psychotropic drug abuse and can not quit or have mental&#xD;
             disorders.&#xD;
&#xD;
          6. Subjects with any severe and/or uncontrolled disease, including:&#xD;
&#xD;
        (1) Unsatisfactory blood pressure control with more than 2 drugs (systolic blood pressure&#xD;
        ≥150mmHg or diastolic blood pressure ≥ 100mmHg) ; (2) Patients with grade ≥2 myocardial&#xD;
        ischemia or infarction, arrhythmias (including QTc≥480ms), and grade ≥2 congestive heart&#xD;
        failure (New York Heart Association classification); (3) Uncontrolled active infections&#xD;
        including bacteria, fungi, parasites or viruses such ascytomegalovirus, Epstein-Barr virus,&#xD;
        and human herpes virus 6; (4) Cirrhosis, active hepatitis; (5) Human immunodeficiency&#xD;
        virus(HIV) positive, active syphilis; (6) Creatinine clearance rate &lt; 30 mL/min,calculated&#xD;
        by Cockcroft Gault formula; (7) Patients with epilepsy and need treatment. 7. Subjects with&#xD;
        evidence of recurrence of primary disease or relapsed after allo-HSCT treatment.&#xD;
&#xD;
        8. There were grade 2 or higher toxicity (except aGVHD) caused by previous allo HSCT&#xD;
        treatment.&#xD;
&#xD;
        9. Subjects who received allo-HSCT more than once in the past. 10. Subjects who received&#xD;
        more than one kind of systemic treatment for Glucocorticoid-Refractory aGVHD.&#xD;
&#xD;
        11. The clinical manifestations were new-onset chronic GVHD or overlapping GVHD syndrome&#xD;
        with both acute and chronic GVHD features.&#xD;
&#xD;
        12. Allergic to the investigational drug or its ingredients. 13. Subjects who used Janus&#xD;
        kinase inhibitor (JAK) therapy after receiving Allo-HSCT.&#xD;
&#xD;
        14. Subjects who participated in other clinical trials within 4 weeks before initial&#xD;
        administration.&#xD;
&#xD;
        15. According to the judgment of the investigator, there are concomitant diseases that&#xD;
        seriously endanger the safety of the subjects or affect the completion of the study, or&#xD;
        subjects who are considered unsuitable for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Depei Wu, Doctor</last_name>
    <phone>0512-67781856</phone>
    <email>drwudepei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Depei Wu, doctor</last_name>
      <phone>0512-67781856</phone>
      <email>drwudepei@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

